PARIS--(BUSINESS WIRE)--Adents, the serialization and traceability software specialist, recently finalized a round of funding of 12 million euros, bringing to 20 million euros the total amount invested in the company over the last 18 months. This increase in capital was signed by Adents’ long time investors NAXICAP Partners, Omnes Capital and CapHorn Invest. The new funding will primarily support the further development of a global network of « solution partners » and gaining footholds in new international markets.
Over the last few years, Adents has emerged as one of the leading providers of versatile and easily deployable serialization and track-and-trace software solutions for the pharmaceutical and life sciences industries.
Serialization is a means of ascribing small groups or even single packages individual identification codes. These codes allow drug manufacturers to track and trace their products throughout the supply chain, which accomplishes a variety of valuable tasks from combating illegal drug counterfeiting to better ensuring drug efficacy and patient safety.
Serialization is mandated to be implemented on thousands of packaging lines in the United States before the end of 2017 per the Drug Supply Chain Security Act (DRCSA), and by the beginning of 2019 in the European Union via the EU Falsified Medicines Directive (EU FMD). Both represent strategic milestones in the serialization market. Simultaneously, Adents has experienced significant growth since the announcement of a strategic collaboration with SIEMENS (NQB:SIEGY) earlier this year.
Although the new round of funding aroused a great deal of interest among prominent international investors, Adents’ executives chose NAXICAP, Omnes Capital and CapHorn Invest, all of whom have supported the growth of the company for many years and confirmed their confidence in Adents’ growth strategy.
"This new round of funding addresses two strategic objectives for the company in the short term, » explains Christophe Devins, CEO and Founding Partner of Adents. « First, we believe it will strengthen our partnership program, with a strong focus on the development of a powerful « solutions partners » network in the U.S. Second, it will support the penetration into promising new international markets, such as the Middle East and Asia. »
Adents Pharma Suite Serialization Software provides the first and only truly standardized and fully configurable serialization software on the market.
Combined with a global network of technological and services partners, the software solution helps secure implementation lead times up to 5 times faster than other solutions, and enables drug manufacturers to address all current and emerging regulatory requirements pertaining to drug serialization.
To date, more than 2 billion unique codes have already been generated and managed globally using Adents software.
# # #
About Adents:
Adents is a software
specialist of unique product identification and traceability helping
pharmaceutical companies and contract manufacturers adapt to market
changes and comply with regulations on drug traceability. Adents Pharma
Suite utilizes user-friendly, standardized software compatible with both
information systems (ERP, MES) and existing production and packaging
equipment. Easily upgradable, the software is designed to address both
current and emerging regulations to help pharma companies remain in
compliance long-term.
Adents Pharma Suite serialization software
was recently awarded an Innovation Award from Medicine Maker, a UK-based
publication focusing on the pharmaceutical manufacturing sector.
Founded
in 2007, Adents operates in Europe, Canada, and in the United States.
For more information, please visit www.adents.com
About Omnes Capital:
Omnes Capital is
a major player in private equity and infrastructure. With €2.1 billion
in assets under management, Omnes capital provides companies with the
capital needed to finance their growth and with key expertise in a
number of areas: Buyout & Growth Capital, Private Debt, Venture Capital,
Renewable Energy, Co-Investment, Secondary Funds of Funds. Omnes Capital
was a subsidiary of Crédit Agricole until March 2012. The firm is now
owned by its employees. Omnes Capital is a signatory to the United
Nations Principles for Responsible Investment (PRI). www.omnescapital.com
About NAXICAP Partners:
One of
France’s leading private equity companies, Naxicap Partners totals €2
billion of capital under management. Committed and responsible
investors, it builds solid, constructive partnerships with the
entrepreneurs it supports to help build on the success of their
projects. A subsidiary of Natixis, the company’s 38 investment
professionals are organized in three teams: Innovation & Growth, Small
Caps and Mid Caps, working from 5 regional offices: Paris, Lyon,
Toulouse, Strasbourg and Nantes. www.naxicap.fr
About CapHorn Invest:
CapHorn Invest
is an independent Venture Capital Firm whose LPs are over 150 business
executives and family offices. Its team relies on this strong network
of experienced business leaders to boost its portfolio companies
and provide them with direct commercial connections to decision makers.
Caphorn invests in companies bringing digital transformation to mature
markets. www.caphorninvest.fr
